
Marsh McLennan
MRSH · NYSE · Insurance
Quotes delayed up to 15 min. Updated 16 Nov, 16:00 New York time
- Market cap
- $100 bn
- Div. yield
- —
- Year to date
- +12,0%
Ratio score
based on 6 metrics as of 16.11.2026 ·
Verdict by our methodology based on current metrics. Not an investment recommendation.
Key metrics
2 ✓ · 3 — · 1 ✕ · 4 n/a · hover over a row or tap it to see the trend
All metrics
| Metric | Value | 5-year median | Industry median |
|---|---|---|---|
| P/E TTM | 24,9 | — | 12,9 |
| Forward P/E | 17,8 | — | 12,6 |
| PEG | 3,3 | — | 1,6 |
| P/S | 3,5 | — | 1,9 |
| EV/EBITDA | 18,6 | — | 11,0 |
| P/FCF | 20,5 | — | 9,2 |
| P/B | 6,8 | — | 2,0 |
Industry median — across 22 profitable companies in “Insurance” in Ratio. Revenue and EPS forecasts for future years and the number of employees are in the paid data plan.
Price chart
Compare with
Choose a stock
Closing prices adjusted for splits and dividends. The S&P 500 index and the intraday chart come later.
Analysts
Ratings, 31 analysts
- Buy
- 12
- Hold
- 18
- Sell
- 1
Beat the EPS forecast in 3 of the last 4 quarters
| Quarter | Estimate | Actual | Surprise |
|---|---|---|---|
| Q3 2026 | 2,01 | 2,03 | Up +0,8% |
| Q2 2026 | 2,96 | 2,96 | Up +0,1% |
| Q1 2026 | 3,29 | 3,29 | Down 0,0% |
| Q4 2025 | 2,01 | 2,12 | Up +5,4% |
Price targets and yearly revenue and EPS forecasts are in the paid data plan. These are analysts' opinions, not our verdict.
Financials in charts
| Metric | Q3'26 | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 6,86 bn | 7,40 bn | 7,60 bn | 6,60 bn | 6,35 bn | 6,97 bn | 7,06 bn | 6,07 bn | 5,70 bn | 6,22 bn | 6,47 bn | 5,55 bn |
| EPS | 1,69 | 2,63 | 2,36 | 1,68 | 1,51 | 2,45 | 2,79 | 1,59 | 1,51 | 2,27 | 2,82 | 1,52 |
| Margin | 11,8% | 17,1% | 15,1% | 12,4% | 11,8% | 17,4% | 19,6% | 13,0% | 13,1% | 18,1% | 21,6% | 13,6% |
| FCF | 1,40 bn | 1,45 bn | −750 m | 2,06 bn | 2,01 bn | 1,61 bn | −677 m | 1,88 bn | 1,84 bn | 1,14 bn | −868 m | 1,66 bn |
From SEC reports. TTM is the sum of 4 quarters; a year is TTM at the end of the calendar year. Forecast bars are in the paid data plan.
Owners
Ownership structure and major holders (13F filings) are in the paid data plan. They are not part of the score or the traffic light.
Insider trades over 12 months
Over 12 months: no purchases, sales $16,3 m.
| Name | Amount | Shares | Price |
|---|---|---|---|
| beswick paul5 Nov 2026 · sale | $151 705 | 713 | $212,77 |
| klisura dean michael23 Oct 2026 · sale | $838 800 | 4 194 | $200,00 |
| mills stacy23 Oct 2026 · sale | $243 000 | 1 215 | $200,00 |
| brennan katherine2 Sep 2026 · sale | $224 915 | 1 197 | $187,90 |
| doyle john q2 Sep 2026 · sale | $3,14 m | 16 656 | $188,51 |
| jones john jude6 Aug 2026 · sale | $1,25 m | 6 500 | $191,96 |
| beswick paul29 Jul 2026 · sale | $141 174 | 713 | $198,00 |
| south martin28 Jul 2026 · sale | $1,35 m | 7 100 | $189,99 |
| yates lloyd m23 Jul 2026 · sale | $2,11 m | 12 000 | $175,65 |
| doyle john q2 Jun 2026 · sale | $2,69 m | 16 656 | $161,71 |
| jones john jude11 Mar 2026 · sale | $410 067 | 2 362 | $173,61 |
| doyle john q4 Mar 2026 · sale | $3,05 m | 16 655 | $183,30 |
| studer nicholas mark3 Mar 2026 · sale | $706 123 | 3 837 | $184,03 |
SEC Form 4. Titles and trading plans are not in the data. They are not part of the score or the traffic light.
About the company
- Industry
- Insurance
- Exchange
- NYSE
- Country
- US
- IPO date
- 4 Jun 1969
- Website
- www.marshmclennan.com
Company description, revenue by segment and region, and the CEO will come later.
Earnings
- Next report
- date not announced
An AI summary of the earnings call will come later.
Peers
| Company | Price | ||||
|---|---|---|---|---|---|
PGRProgressive Corporation | $237,33 | 64★★★★★★★★would watch | 11,8 | +7,7% | 12,7% |
AJGArthur J. Gallagher & Co. | $287,00 | 67★★★★★★★★★would watch | 42,7 | +25,6% | 10,4% |
AONAon plc | $343,12 | 79★★★★★★★★★would consider | 18,3 | +3,8% | 22,6% |
CBChubb Limited | $381,28 | 71★★★★★★★★★would consider | 12,8 | +5,7% | 18,2% |
ALLAllstate | $270,43 | 71★★★★★★★★★would consider | 5,7 | +5,1% | 16,6% |
Ratio — a score by our methodology, not an investment recommendation.




